XML 51 R28.htm IDEA: XBRL DOCUMENT
v3.24.1

Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss | 12 Months Ended
--- | ---
Dec. 31, 2023
Disclosure of supplementary information to the statements of profit and lost and other comprehensive loss [Abstract] |
Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss |
Note 22: | Supplementary Information to the Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss
| a. | Additional information on Revenues:
Major customers: BARDA contributed 56%, 51% and 76% of the Company’s total revenues in 2023, 2022 and 2021 respectively. Vericel contributed 4% and 28% of the Company’s total revenues in 2023 and 2022 respectively. MTEC contributed 10% and 2.8% of the Company’s total revenues in 2023 and 2022 respectively (see also Note 18). No other customer contributed 10% or more of the Company’s revenues in 2023, 2022 and 2021. Geographic information: The revenues reported in the financial statements are based on the location of the customers, as follows:
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
USA (see also Note 18a, 18b, 18c) |  |  | 13,078 |  |  |  | 21,872 |  |  |  | 18,102 |
EU and other international markets |  |  | 5,608 |  |  |  | 4,624 |  |  |  | 5,661 |
|  |  | 18,686 |  |  |  | 26,496 |  |  |  | 23,763 |
| b. | Cost of Revenues:
| 1. | Cost of Revenues from sale of products
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Salary and benefits (including share-based compensation) |  |  | 2,703 |  |  |  | 1,828 |  |  |  | 2,047 |
Subcontractors |  |  | 230 |  |  |  | 58 |  |  |  | 190 |
Depreciation and amortization |  |  | 672 |  |  |  | 426 |  |  |  | 559 |
Cost of materials |  |  | 916 |  |  |  | 636 |  |  |  | 1,039 |
Other manufacturing expenses |  |  | 1,207 |  |  |  | 779 |  |  |  | 906 |
Decrease (increase) in inventory of finished products |  |  | (801 | ) |  |  | (543 | ) |  |  | 242 |
|  |  | 4,927 |  |  |  | 3,184 |  |  |  | 4,983 |
| 2. | Cost of Revenues from development services
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Salary and benefits |  |  | 1,995 |  |  |  | 1,691 |  |  |  | 2,003 |
Subcontractors |  |  | 8,182 |  |  |  | 8,138 |  |  |  | 7,904 |
|  |  | 10,177 |  |  |  | 9,829 |  |  |  | 9,907 |
| 3. | Cost of Revenues from license agreements
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Salary and benefits |  |  | 4 |  |  |  | 38 |  |  |  | 102 |
Royalties payments |  |  | - |  |  |  | 280 |  |  |  | - |
|  |  | 4 |  |  |  | 318 |  |  |  | 102 |
Total Cost of Revenues |  |  | 15,108 |  |  |  | 13,331 |  |  |  | 14,992 |
| c. | Research and development expenses:
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Salary and benefits (including share-based compensation) (1) |  |  | 3,148 |  |  |  | 4,494 |  |  |  | 2,864 |
Subcontractors |  |  | 2,833 |  |  |  | 4,054 |  |  |  | 6,323 |
Depreciation and amortization |  |  | 396 |  |  |  | 571 |  |  |  | 396 |
Cost of materials |  |  | 785 |  |  |  | 572 |  |  |  | 347 |
Other research and development expenses |  |  | 305 |  |  |  | 490 |  |  |  | 326 |
Total Research and development |  |  | 7,467 |  |  |  | 10,181 |  |  |  | 10,256 |
| (1) | The salary costs for the year ended December 31,2022 includes one-time payment of $205 derived from termination agreement with the CMO of the company.
| d. | Selling and marketing expenses:
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Salary and benefits (including share-based compensation) |  |  | 1,991 |  |  |  | 1,637 |  |  |  | 1,643 |
Marketing and consulting |  |  | 1,637 |  |  |  | 1,152 |  |  |  | 627 |
Depreciation and amortization |  |  | 50 |  |  |  | 49 |  |  |  | 44 |
Shipping and delivery |  |  | 356 |  |  |  | 385 |  |  |  | 490 |
Registration and marketing license fees |  |  | 810 |  |  |  | 502 |  |  |  | 584 |
|  |  | 4,844 |  |  |  | 3,725 |  |  |  | 3,388 |
| e. | General and administrative expenses:
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Salary and benefits (including share‑based compensation) |  |  | 3,521 |  |  |  | 3,344 |  |  |  | 2,905 |
Professional fees |  |  | 2,189 |  |  |  | 2,589 |  |  |  | 2,480 |
Depreciation and amortization |  |  | 185 |  |  |  | 225 |  |  |  | 239 |
Other |  |  | 873 |  |  |  | 762 |  |  |  | 724 |
|  |  | 6,768 |  |  |  | 6,920 |  |  |  | 6,348 |
| f. | Other (income) expenses:
The other one-time income amounted $211 for the year ended December 31, 2023, is associated with the termination of sub-lease agreement (see note 11a). The other one-time expenses amounted $684 for the year ended December 31, 2022, are associated with the management changes and FDA milestone payment fee (see Note 18b).
| g. | Financial income and expense:
|  | Year ended December 31 |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Financial income: |  |  |  |  |  |  |  |  |
Interest income |  |  | 2,341 |  |  |  | 270 |  |  |  | 11 |
Revaluation of liabilities in respect of IIA grants |  |  | - |  |  |  | 132 |  |  |  | - |
Revaluation of Warrants |  |  | 8,310 |  |  |  | - |  |  |  | - |
Exchange differences, net |  |  | - |  |  |  | 59 |  |  |  | - |
|  |  | 10,651 |  |  |  | 461 |  |  |  | 11 |
Financial expense: |  |  |  |  |  |  |  |  |  |  |  |
Revaluation of liabilities in respect of IIA grants |  |  | 427 |  |  |  | - |  |  |  | 903 |
Financing income on net investment in lease |  |  | 274 |  |  |  | 102 |  |  |  | 120 |
Finance expenses in respect of deferred revenues |  |  | 8 |  |  |  | 54 |  |  |  | 143 |
Revaluation of liabilities in respect of TEVA |  |  | 468 |  |  |  | 533 |  |  |  | 590 |
Exchange differences, net |  |  | 654 |  |  |  | - |  |  |  | 511 |
Revaluation of Warrants |  |  | - |  |  |  | 8,977 |  |  |  | - |
Issuance expenses of warrants through profit and loss |  |  | - |  |  |  | 1,911 |  |  |  | - |
Other |  |  | 61 |  |  |  | 60 |  |  |  | 47 |
|  |  | 1,892 |  |  |  | 11,637 |  |  |  | 2,314 |
Financial income (expenses), net |  |  | 8,759 |  |  |  | (11,176 | ) |  |  | (2,303 | )

X
- Definition The entire disclosure for supplementary information to the statements of profit and lost and other comprehensive loss. + References No definition available. + Details
Name: | mdwd_DisclosureOfSupplementaryInformationToStatementsOfComprehensiveLossExplanatory
Namespace Prefix: | mdwd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | mdwd_DisclosureOfSupplementaryInformationToStatementsOfProfitAndLostAndOtherComprehensiveLossAbstract
Namespace Prefix: | mdwd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration